New Assay Aids in Prediction of Esophageal Cancer

Diagnovus announced the launch of the Engauge GI–Barrett’s Esophagus, the first available genomic assay to aid in predicting the risk of progression to high-grade dysplasia or esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus.

RELATED: Oncology Resource Center

Engauge GI–Barrett’s Esophagus is a proprietary gene expression assay that uses RT-PCR to determine the methylation profile of an 8-gene panel. Methylation is a signaling tool used by cells that is common in cancer development and may play a role in the carcinogenic process.

The assay uses routine biopsy material taken during endoscopic surveillance and can be performed in a highly reproducible and accurate manner using formalin-fixed paraffin embedded diagnostic biopsy tissue.

For more information call (855) 642-8438 or visit Diagnovus.com.